Scleromyositis (scleroderma/polimyositis overlap) is an entity

Journal of the European Academy of Dermatology and Venereology

Volumn 18, Issue 3, 2004, Pages 265-266

  Jablonska, S ^a   Blaszyk, M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; HLA DQA1 ANTIGEN; HLA DR ANTIGEN; HLA DR3 ANTIGEN;

ANTIBODY TITER; ARM EDEMA; ARTHRALGIA; AUTOIMMUNITY; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE COURSE; DISEASE SEVERITY; DYSPHAGIA; EDITORIAL; ERYTHEMA; FACE DISORDER; FACE EDEMA; GENE FREQUENCY; HAPLOTYPE; HUMAN; IMMUNODIFFUSION; IMMUNOFLUORESCENCE; IMMUNOGENETICS; INTERSTITIAL LUNG DISEASE; KERATODERMA; MOLECULAR TYPING; MUSCLE ATROPHY; MYALGIA; PAPULE; POIKILODERMA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SKIN DEFECT; SYMPTOMATOLOGY;

AUTOANTIBODIES; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; POLYMYOSITIS; PROGNOSIS; RISK ASSESSMENT; SCLERODERMA, LOCALIZED; SYNDROME;

EID: 2442447400     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00869.x     Document Type: Editorial

References (16)

1. Torök L, Danko K, Cserni G, Szues G. PM-Scl antibody positive scleroderma with polymyositis (Mechanic's hand: clinical aid in the diagnosis). JEADV 2004; 18: 356-359.
2. Jablonska S, Chorzelski TP, Blaszczyk M et al. Scleroderma/polymyositis overlap syndromes and their immunologic markers. Clin Dermatol 1993; 10: 457-472.
3. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW et al. Clinical, serological, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 1257-1266.
4. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis specific autoantibodies define useful homogenous patient groups. Medicine (Baltimore) 1991; 34: 1391-1396.
5. Bhaszczyk M, Jablonska S, Szymanska-Jagiello W et al. Childhood scleromyositis: an overlap syndrome associated with PM-Scl antibody. Pediatric Dermatol 1991; 8: 1-8.
6. Jablonska S, Blaszczyk M. Scleroderma overlap syndromes. In: Mallia C, Uitto J, eds. Rheumaderm. Current Issues in Rheumatology and Dermatology. Kluwer Academic/Plenum Publishers, New York, 1999: 85-92.
7. Jablonska S, Bhaszczyk M. Scleromyositis: a scleroderma/polymyositis overlap syndrome. Clin Rheumatol 1998; 17: 465-467.
8. Marguerie C, Bunn CC, Copier J et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992; 71: 321-335.
9. Reichlin M, Maddison PJ, Targoff I et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984; 4: 40-44.
10. Alderuccio F, Chan EK, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75 kD acidic protein of the nucleolar complex. J Exp Med 1991; 173: 941-952.
11. Alarcon-Segovia D, Cardiel MM. Comparison between three diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989; 16: 328-334.
12. Maddison PJ, Jablonska S. Overlap syndromes. In: Kater L, Baart de la Faille H, eds. Multi-Systemic Autoimmune Diseases. Elsevier, Amsterdam, 1995: 227-240.
13. Oddis CV, Okana Y, Rudert WA et al. Serum autoantibody to the nuclealar antigen PM-Scl: clinical and immunogentic associations. Arthritis Rheum 1992; 35: 1211-1217.
14. Ehrlich H, Bugawan T, Begovich AB et al. HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. Eur J Immunogenet 1991; 18: 33-55.
15. Miller FW. Genetics of autoimmune diseases. Exp Clin Immunogenet 1995; 12: 182-190.
16. Matej H, Nowakowska B, Pacynska J et al. HLA-A, B, C and DR gene and haplotype frequencies in 600 Poles by maximum likelihood method of gene counting. Arch Immunol Ther Exp (Warsz) 1992; 40: 151-156.